NCT00354302 2020-04-02
Bone Mineral Density in Postmenopausal Women With Primary Breast Cancer Who Are Receiving Treatment on Clinical Trial
Canadian Cancer Trials Group
Phase 3 Completed
Clinical Trials
10 trialsNCT00639210 2019-02-26
BREX
Finnish Breast Cancer Group
Phase 3 Completed
NCT00107263 2016-12-06
Zoledronate in Preventing Bone Loss in Postmenopausal Women Who Are Receiving Letrozole for Stage I, Stage II, or Stage IIIA Breast Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00022087 2016-07-19
Zoledronate, Calcium, and Vitamin D in Preventing Bone Loss in Women Receiving Adjuvant Chemotherapy for Breast Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00054418 2016-07-13
Risedronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy for Primary Breast Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00049452 2014-01-06
Zoledronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy After Surgery For Early Stage Breast Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00859703 2013-10-31
RISAROS
Hospices Civils de Lyon
Phase 3 Completed
NCT00324714 2012-11-29
Risedronate in Improving Bone Mineral Density and Bone Health in Postmenopausal Women With Ductal Carcinoma In Situ Enrolled in Clinical Trial CRUK-IBIS-II-DCIS
ETOP IBCSG Partners Foundation
Phase 3 Withdrawn
NCT00369850 2012-07-27
Bone Density and Bone Loss in Postmenopausal Women With Breast Cancer Receiving Treatment in Clinical Trial IBCSG-1-98
ETOP IBCSG Partners Foundation
Phase 3 Completed
NCT00332709 2011-11-16
Safety/Efficacy of Letrozole Monotherapy or in Combination With Zoledronic Acid as Extended Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer
Novartis
Phase 3 Completed